Lupin Limited — Updates, 12-08-2025: Press Release

Lupin has partnered with Sandoz Group AG to market and commercialize its biosimilar ranibizumab across multiple regions. Lupin will manage manufacturing and regulatory submissions, while Sandoz will oversee commercialization in the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, Malaysia, and Canada. This strategic collaboration expands Lupin's global reach for its key biologic therapy, targeting conditions like Wet AMD. The deal leverages Sandoz's commercial network, potentially boosting Lupin's biosimilar revenue and market presence.